Literature DB >> 16156313

Left ventricular assist devices as bridge to heart transplantation in congestive heart failure with pulmonary hypertension.

Haissam Haddad1, Wael Elabbassi, Sherif Moustafa, Ross Davies, Thierry Mesana, Paul Hendry, Roy Masters, Tofy Mussivand.   

Abstract

Severe pulmonary hypertension (PH) has been considered a significant contraindication to cardiac transplantation. Ongoing clinical experience, however, has shown that temporary support using left ventricular assist devices (LVADs) in these patients can result in significant reductions in PH. A comprehensive review of the available literature regarding the use of LVADs in heart failure patients with PH was conducted. The existing literature to date supports the use of LVADs in heart failure patients with PH and demonstrates that significant reductions in PH in these patients can be achieved. This subsequently allows for safe and effective cardiac transplantation in patients who were previously excluded from this modality. For heart failure patients with severe PH, the use of LVADs can provide significant benefits by significantly reducing PH and allowing subsequent staged transplantation.

Entities:  

Mesh:

Year:  2005        PMID: 16156313     DOI: 10.1097/01.mat.0000169125.21268.d7

Source DB:  PubMed          Journal:  ASAIO J        ISSN: 1058-2916            Impact factor:   2.872


  12 in total

1.  New Diagnostic and Therapeutic Strategies for Pulmonary Hypertension Associated with Left Heart Disease.

Authors:  Scott Feitell; Miriam Jacob
Journal:  Curr Treat Options Cardiovasc Med       Date:  2016-03

2.  Pulsatile left ventricular assist device support as a bridge to decision in patients with end-stage heart failure complicated by pulmonary hypertension.

Authors:  Pradeep K Nair; Robert L Kormos; Jeffrey J Teuteberg; Michael A Mathier; Christian A Bermudez; Yoshiya Toyoda; Mary Amanda Dew; Marc A Simon
Journal:  J Heart Lung Transplant       Date:  2010-02       Impact factor: 10.247

3.  Mechanical circulatory support in pediatrics.

Authors:  Fabrizio Gandolfo; Fabrizio De Rita; Asif Hasan; Massimo Griselli
Journal:  Ann Cardiothorac Surg       Date:  2014-09

Review 4.  Regression of pathological cardiac hypertrophy: signaling pathways and therapeutic targets.

Authors:  Jianglong Hou; Y James Kang
Journal:  Pharmacol Ther       Date:  2012-06-29       Impact factor: 12.310

Review 5.  Right ventricular pulmonary hypertension.

Authors:  Marco Guazzi; Serenella Castelvecchio; Francesco Bandera; Lorenzo Menicanti
Journal:  Curr Heart Fail Rep       Date:  2012-12

Review 6.  Left ventricular dysfunction with pulmonary hypertension: part 2: prognosis, noninvasive evaluation, treatment, and future research.

Authors:  Andreas P Kalogeropoulos; Vasiliki V Georgiopoulou; Barry A Borlaug; Mihai Gheorghiade; Javed Butler
Journal:  Circ Heart Fail       Date:  2013-05       Impact factor: 8.790

Review 7.  Physiologic effects of continuous-flow left ventricular assist devices.

Authors:  Aaron H Healy; Stephen H McKellar; Stavros G Drakos; Antigoni Koliopoulou; Josef Stehlik; Craig H Selzman
Journal:  J Surg Res       Date:  2016-01-20       Impact factor: 2.192

Review 8.  Pulmonary Vascular Disease: Hemodynamic Assessment and Treatment Selection-Focus on Group II Pulmonary Hypertension.

Authors:  Bhavadharini Ramu; Brian A Houston; Ryan J Tedford
Journal:  Curr Heart Fail Rep       Date:  2018-04

9.  PDE5A inhibitor treatment of persistent pulmonary hypertension after mechanical circulatory support.

Authors:  Ryan J Tedford; Anna R Hemnes; Stuart D Russell; Ilan S Wittstein; Mobusher Mahmud; Ari L Zaiman; Stephen C Mathai; David R Thiemann; Paul M Hassoun; Reda E Girgis; Jonathan B Orens; Ashish S Shah; David Yuh; John V Conte; Hunter C Champion
Journal:  Circ Heart Fail       Date:  2008-11       Impact factor: 8.790

10.  Role of paediatric assist device in bridge to transplant.

Authors:  Roland Hetzer; Mariano Francisco Del Maria Javier; Eva Maria Delmo Walter
Journal:  Ann Cardiothorac Surg       Date:  2018-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.